The second-generation FLT3 inhibitor gilteritinib was approved for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation, as detected by an FDA-approved test. The gene discussed is FLT3; the disease is acute myeloid leukemia.